<DOC>
	<DOC>NCT00679939</DOC>
	<brief_summary>The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus</brief_summary>
	<brief_title>Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Female, &gt;55 to &lt;80 years &gt;5 years menopausal Type 2 Diabetes Mellitus (T2DM) diagnosis according to American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), Canadian Diabetes Association (CDA), World Health Organization/International Diabetes Federation (WHO/IDF) Drugna√Øve (HbA1c &lt; or = 9.0%); OR Prior monotherapy, submaximal doses of metformin (&lt; or = 1000mg Metformin), sulfonylureas (&lt; or = 5mg Glyburide, &lt; or = 10mg Glipizide or &lt; or = 8mg glimepiride) or full dose Januvia (100mg) (HbA1c &lt; or = 8.5%); OR Prior monotherapy, &gt; submaximal doses of metformin (&gt;1000mg) or sulfonylureas (&gt;5mg Glyburide, &gt;10mg Glipizide or &gt;8mg glimepiride) (HbA1c &lt; or = 7.0%) Weighs &lt;300 lbs (136.4 kg) Two or more vertebra (L1L4) suitable for BMD measurement by dual xray absorptiometry (DXA) Absolute BMD value consistent with Tscore &gt;2.5 at femoral neck, lumbar spine and total hip Type 1 Diabetes Mellitus (T1DM) or history of diabetic ketoacidosis (DKA) Renal or hepatic disease (clinically significant) Hepatocellular reaction, severe edema, or medically serious fluid event associated with thiazolidinedione (TZD) Recent (&lt;6mos) history or clinical intervention for angina or myocardial infarction or is taking nitrates Any stage of heart failure, i.e. New York Heart Association (NYHA) class IIV Systolic BP &gt;160mmHg or diastolic BP &gt;90mmHg while on antihypertensive Hypersensitivity to TZDs, biguanides Prior treatment with two or more oral antidiabetic (OAD) agents Bilateral hip replacements Concurrent diseases affecting bone metabolism Active malabsorption syndrome Serum calcium outside the central lab reference range Thyroid replacement therapy, serum thyroid stimulating hormone (TSH) must be within range Vitamin D deficiency Previous treatment with: strontium, intravenous (IV) bisphosphonate, fluoride, hormones, calcineurin inhibitors or methotrexate Chronic systemic corticosteroid [e.g. glucocorticoid, mineralocorticoid] treatment of no more than two intraarticular injections within the past year or use of oral parenteral, or longterm, highdose inhaled corticosteroids</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>bone</keyword>
	<keyword>x-ray absorptiometry</keyword>
	<keyword>bone biomarkers</keyword>
	<keyword>dual-energy</keyword>
	<keyword>bone mineral density</keyword>
</DOC>